FDA approved BEVYXXA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208383 Full prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf
Stock and macro calendar http://www.precisiontrade365.com/stock-and-macro-calendar/ Tomorrow starts of a new month and these are some biotech ideas to watch in June. #CARA- Top-line data expected in 2Q, phase 2b trial Oral CR845 http://ir.caratherapeutics.com/releasedetail.cfm?ReleaseID=1024907 #CLVS- ARIEL3 results end of June http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle_Print&ID=2269437 #GEMP- Top-line COLBALT1-Phase 2b trial expected late June http://ir.gemphire.com/phoenix.zhtml?c=254241&p=irol-newsArticle&ID=2271147 Thanks for reading. ~PT365
#PANW Palo Alto Networks Inc, Q3 adjusted EPS 61c vs 55c consensus, revenue $431.80m vs $411.92m on April 25, 2017 when stock was at $100.40, our team highlighted the June 16, 120c with 6,767 volumes ask price at $2.90. With today closed, the June 16, 120c ask at $5.20 for nearly double, but [...]
#AERI Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results https://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-roclatan-200100906.html #PBYI Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib http://investor.pumabiotechnology.com/press-release/puma-biotechnology-receives-fda-advisory-committee-support-neratinib #RDUS Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis https://finance.yahoo.com/news/radius-announces-positive-top-line-200000822.html
Stock and Macro calendar http://www.precisiontrade365.com/stock-and-macro-calendar/ #PBYI released FDA 152 pages of briefing document here https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559728.pdf More content from FDA.gov website https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm559714.htm Always do your own due diligence to be informed. These are idea and opinion only. some highlights from briefing documents: Before and after charts share to members Before, as of May 19, 2017 closed. after, [...]
These are ideas only. Always do your own due diligence. Details notes and guides are for members. #CLVS- catalyst top-line ARIEL3 data anticipated end of June http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle&ID=2269437 2. #PBYI- catalyst Oncology Drugs Advisory Committee, May 24. Stocks and Macro calendar http://www.precisiontrade365.com/stock-and-macro-calendar/
Elite small cap biotech pick hit target. Trim and trail. Blog article on 3/07/17 http://www.precisiontrade365.com/new-small-cap-biotech-idea-3-7-17/ Chart on March 7, 2017 pick for elite membership. after chart as of April 4/25/17
CAPR Capricor Therapeutics to Report Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy. http://finance.yahoo.com/news/capricor-therapeutics-report-six-month-203000017.html Conference Tuesday, April 25 at 8am ET. Share +19.74% after hours SRPT +0.47% after hours. Watch for reaction trade tomorrow Charts:
Fresenius Kabi to acquired Akorn, a $4.30 billion or $34 per share. Press release http://finance.yahoo.com/news/fresenius-kabi-acquire-akorn-205800399.html Stock closed on April 24, 2017 at $32.72 Here is our chat and notes to member on Friday 7, 2017.
Good evening newsletters subscribers, We hope you like our public newsletters information in the past months, we would like to invite you to join our FREE TRIAL chat room and site access for the week, April 17-21,2017. If you are interested, email to us support@precisiontrade365.com with subject "Free trial". NO CREDIT CARD needed. Our team [...]